Nanollose Full Year 2024 Earnings: AU$0.007 loss per share (vs AU$0.009 loss in FY 2023)
Nanollose (ASX:NC6) Full Year 2024 Results
Key Financial Results
- Revenue: AU$308.5k (down 25% from FY 2023).
- Net loss: AU$1.16m (loss narrowed by 14% from FY 2023).
- AU$0.007 loss per share (improved from AU$0.009 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Nanollose shares are down 19% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 6 warning signs for Nanollose (5 make us uncomfortable!) that you need to be mindful of.
Valuation is complex, but we're here to simplify it.
Discover if Nanollose might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ASX:NC6
Nanollose
A biomaterials company, engages in the research and development, and promotion of microbial cellulose technologies in Australia.
Medium-low with worrying balance sheet.